What Are the Side Effects of Ozempic? What the Research Actually Shows

Ozempic has become one of the most talked-about medications in modern medicine, and for good reason. Research shows semaglutide produces roughly 15% total body weight loss at 68 weeks — the largest reduction ever documented for an obesity medication. But with that kind of effectiveness comes a very real question: what’s the cost? If you’re considering Ozempic, already on it, or just trying to understand what all the noise is about, here’s what the science actually says about its side effect profile.

The Most Common Side Effects Are Gastrointestinal — and Usually Temporary

The side effect story with Ozempic starts and largely ends in the gut. Nausea, diarrhea, vomiting, and constipation are the most frequently reported complaints, and they show up consistently across both clinical trials and real-world data. A 2024 JAMA review of antiobesity medications found that nausea affects 28–44% of semaglutide users, diarrhea affects 21–30%, and constipation impacts 11–24% — numbers that sound alarming until you understand the context.

These symptoms are almost always tied to dose escalation. Semaglutide works by slowing gastric emptying and acting on GI receptors, which means your digestive system needs time to adapt as the dose increases. Most men who push through the initial ramp-up period find that symptoms diminish significantly over weeks. Eating smaller meals, avoiding high-fat foods during the adjustment phase, and staying well-hydrated all help. The discomfort is real, but it’s rarely a reason to abandon the medication entirely.

A comprehensive 2021 safety review in Frontiers in Endocrinology confirmed that semaglutide’s GI effects are predominantly mild-to-moderate and transient, and that no unexpected safety signals have emerged across its extensive phase 3 trial programs. That’s a meaningful finding — this drug has been studied in tens of thousands of patients, and the serious adverse event rate has remained low.

The Rarer Risks Worth Understanding

Where things get more nuanced is with the less common but more serious potential risks. Gallbladder disease — specifically gallstones (cholelithiasis) — is one of the few areas where semaglutide has shown a statistically meaningful increase in risk. Rapid weight loss itself is a known driver of gallstone formation, so this may be partly a consequence of the medication’s effectiveness rather than a direct pharmacological effect. Either way, if you have a history of gallbladder issues, that conversation with your doctor needs to happen before starting.

Pancreatitis and pancreatic cancer have been theoretical concerns since GLP-1 receptor agonists first emerged. The Frontiers in Endocrinology safety review concluded there is no definitive evidence linking semaglutide to increased pancreatic cancer risk, though the authors note that definitive conclusions are difficult given the rarity of the condition. Similarly, thyroid C-cell tumors have been flagged in rodent studies, which is why Ozempic carries a black box warning for medullary thyroid carcinoma — but this concern has not translated into a documented signal in human populations. People with a personal or family history of MTC or MEN2 syndrome should not use the medication.

Diabetic retinopathy complications are another area that deserves attention. Research indicates that patients with pre-existing diabetic eye disease who experience rapid glucose reduction may face a transient worsening of retinopathy — a phenomenon seen with other aggressive glucose-lowering therapies as well. If you’re a diabetic man with known retinal complications, regular ophthalmology monitoring is non-negotiable while on semaglutide.

Real-world data adds important texture here. A 2025 narrative review in Diabetes, Obesity & Metabolism found no clear increase in risks of severe events like pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm in observational studies of GLP-1 users — though the authors appropriately flag that evidence around rare outcomes and eye disease needs further investigation. Discontinuation rates of 20–50% in the first year largely trace back to GI side effects and cost, not serious medical events.

The 2025 SURMOUNT-5 head-to-head trial comparing tirzepatide and semaglutide reinforced that both medications share a similar GI-dominant side effect profile, with most adverse events being mild to moderate and clustered during dose escalation — a pattern that holds across the entire GLP-1 drug class.

The Takeaway

Ozempic’s side effect profile is manageable for most men who approach it with realistic expectations. The GI symptoms are common but typically temporary, the serious risks are rare and largely context-dependent, and the overall risk-to-benefit ratio is favorable — particularly for men carrying excess weight that’s already straining their metabolic and cardiovascular health. That said, no medication is a free lunch. Working closely with a physician, monitoring for the specific risks relevant to your health history, and pairing the medication with sound nutrition and resistance training to protect muscle mass are what separate men who get real, lasting results from those who quit early or regain everything when they stop.